New: a trial court in 1 of every 10 U.S. counties. Read the post
Court Rules
All enforcement actions
InvestigationLow Risk

Texas Attorney General Ken Paxton Opens Investigation into Southern Poverty Law Center for Funding Extremist Groups It Publicly Opposed

Southern Poverty Law CenterMay 18, 2026Texas Attorney General

Summary

Texas Attorney General Ken Paxton opened an investigation into the Southern Poverty Law Center (SPLC) over allegations that the organization deceived donors by using millions of dollars in contributions to fund extremist groups including the Ku Klux Klan, which it publicly claimed to oppose. The SPLC was indicted on federal fraud charges in April 2026 for secretly paying leaders of these groups without disclosing the payments to donors. The Texas OAG issued a Civil Investigative Demand to SPLC to probe deceptive donor solicititation and other potential violations of Texas law.

Violation Types

Entity Details

Entity

Southern Poverty Law Center

Industry

Other

Official Sources

Source Evidence

Entity Name
"Southern Poverty Law Center (“SPLC”)"
Event Type
"Attorney General Ken Paxton has opened an investigation into the Southern Poverty Law Center (“SPLC”)"
Summary
"SPLC was indicted on federal fraud charges for improperly raising millions of dollars to secretly pay leaders of the Ku Klux Klan (“KKK”) and other groups."
Summary
"donors were not informed that their contributions could be used to financially support individuals affiliated with groups that SPLC claimed to be opposing."
Summary
"Attorney General Paxton is investigating the organization to determine the extent of deceptive donor solicitations and other violations of Texas law."

Related Enforcement Actions

TX

PDD Holdings, Inc. and WhaleCo Inc. (doing business as Temu)

$3.0M

Texas Attorney General Ken Paxton announced a settlement requiring Temu to protect Texans’ sensitive personal data from exposure to the Chinese Communist Party and to strengthen product-safety practices. Temu must pay Texas $3 million, comply with data-security requirements backed by a potential $8 million annual penalty, conduct annual independent product testing, and take specified action on products found to contain harmful substances.

TX

Albertsons Companies, Inc.

$773.0M

Texas Attorney General Ken Paxton announced that a multistate coalition had secured an opioid settlement with Albertsons, which would require the grocery chain to pay more than $773 million nationally once final. Texas and its political subdivisions may receive up to $57.8 million for opioid abatement; the release does not identify privacy violations.

TX

Gerber Products Company and Nestlé USA, Inc.

Texas Attorney General Ken Paxton sued Gerber Products Company and Nestlé USA, Inc., alleging that Gerber made deceptive safety and testing claims while its baby food contained dangerous levels of toxic heavy metals. The lawsuit asserts claims under the Texas Deceptive Trade Practices Act; the release does not report a settlement, monetary penalty, or court order.

TX

Rubinsky Roofing LLC

$1.5M

The Texas Attorney General obtained a judgment holding Rubinsky Roofing LLC liable for 27 violations of the Texas Deceptive Trade Practices Act, including deceptive practices involving older consumers and payment for unnecessary or unfinished repairs. The judgment requires more than $1.5 million in civil penalties, allocates at least $500,000 to consumer restitution, and permanently bars the company and its owner from the practices at issue.

TX

UnitedHealth Group, Inc.

The Texas Attorney General opened an investigation into UnitedHealth Group over allegations that its insurance-benefit administration and patient-care decisions denied Texans medically necessary healthcare. The AG issued Civil Investigative Demands to collect evidence; the release announces no penalty or remedy.

TX

Tris Pharmaceuticals

$7.5M

Texas Attorney General Ken Paxton announced a $7.5 million settlement with Tris Pharmaceuticals over alleged misrepresentations about the efficacy of Dyanavel XR, an ADHD drug marketed for children. The release says the company overstated the drug’s efficacy and directed sales representatives to make misleading claims to doctors, including Medicaid providers.